Thursday, February 5, 2026
NTT Precision Medicine Corporation
St. Marianna University School of Medicine
BC Platforms
St. Marianna University School of Medicine joins NTT Precision Medicine's "Japan Precision Medicine Platform (JPP)" as a Data Partner
~ Strengthening the Utilization of Advanced Medical Data and International Research Collaboration ~
NTT Precision Medicine Corporation (NTT Precision Medicine, Chiyoda-ku, Tokyo; President and CEO: Koji Korekawa) and BC Platforms (Switzerland; CEO: Mukhtar Ahmed) announce that St. Marianna University School of Medicine has joined the Japan Precision Medicine Platform (JPP)*1 as a data partner, and that a data partnership agreement has been concluded.
As a regional core hospital, St. Marianna University provides advanced medical care across a wide range of clinical fields while actively promoting medical research and education, possessing diverse and high-quality clinical data. This participation will further expand JPP's domestic medical institution network, accelerating the establishment of an environment enabling researchers and pharmaceutical companies to safely and efficiently access Japan's real-world data (RWD).
JPP is Japan's first comprehensive medical data federated analysis platform, jointly developed by NTT Precision Medicine and BC Platforms. It utilizes the international standard model "OMOP CDM" and BC Platforms’ federated data architecture and technology*2, which enables use of BC Platforms’ Trusted Research Environment (TRE)*3 to enable secure access to hospital data.
■ Key Benefits of St. Marianna University School of Medicine's Participation
・The participation of this university, which excels in rare disease diagnosis and research, significantly expands available real-world data (RWD) on rare and intractable diseases, advancing the analysis of patient cohorts that are difficult to obtain.
・Leveraging the JPP framework enables detailed pathophysiological analysis and treatment evaluation in the rare disease field, which was previously difficult for individual medical institutions. This facilitates the creation of innovative treatments by pharmaceutical companies and healthcare researchers.
・Collaboration with domestic and international research institutions and pharmaceutical companies will overcome the challenge of insufficient case numbers for rare diseases, accelerating international joint research and multi-center consortium analyses. This is expected to generate new evidence for patients with intractable diseases.
・Moving forward, establishing a TRE environment that securely provides high-quality intrahospital rare disease data to external researchers will create a model case for "advancing analysis without moving data" in the high-social-need field of rare diseases, broadly contributing to the advancement of rare disease research in Japan.
Endorsement Comment
Yoshihisa Yamano, Center for Clinical & Translational Science Director,Professor and Chair, Department of Neurology, St. Marianna University School of Medicine
St. Marianna University School of Medicine's participation in JPP is a highly significant step that propels the utilization of medical data to a new stage. I am confident that establishing an environment where researchers both domestically and internationally can safely access high-quality real-world data will accelerate the elucidation of complex disease pathologies and the creation of innovative treatments more than ever before. The integration of our university's long-established clinical research infrastructure with JPP's and BC Platforms’ advanced data analytics platform will contribute to creating new knowledge that paves the way for the future of healthcare. We will promote data utilization that bridges research and clinical practice, prioritizing safety and transparency above all else, to deliver better healthcare to all patients.
NTT Precision Medicine Corporation
Masaaki Tabata, Head of Data Platforms Business, Vice President, Member of the Board
The addition of St. Marianna University School of Medicine as a JPP data partner represents a significant step forward for the utilization of medical information in Japan. We expect that the secure utilization of high-quality clinical data, including data on intractable and rare diseases, will further accelerate advanced research and development by pharmaceutical companies and research institutions. NTT Precision Medicine will collaborate with more medical institutions through JPP, which combines BC Platforms’ Trusted Research Environment (TRE) and federated technology, to maximize the value of Japan's medical data.
BC Platforms
Senior Vice President of Life Sciences and Healthcare Sales for JAPAC (Japan and Asia Pacific)
Andrew O’Brien
BC Platforms is pleased to support the connection of Japan’s valuable healthcare data to the global research community through the collaboration between JPP and St. Marianna University School of Medicine. By leveraging our federated data architecture and advanced analytics technology, we enable sophisticated real-world data analysis while ensuring that sensitive data remains securely within each hospital environment. This approach contributes to the generation of new insights across a broad range of research areas, including intractable and rare diseases. We will continue to deepen our collaboration with NTT Precision Medicine and Japanese medical institutions, supporting researchers and pharmaceutical companies both in Japan and internationally with a secure, trusted, and globally aligned data analysis environment.
Strengths and Roles of Each Company
BC Platforms
・Global healthcare data, analytics and technology
・Implementation track record at two domestic institutions (RIKEN: Institute of Physical and Chemical Research; JIHS: Japan Institute for Health Security (formerly NCGM: National Center for Global Health and Medicine))
NTT Precision Medicine
・Primary provider of JPP services
Media Inquiries
NTT Precision Medicine Corporation
Data Platforms Business Division
Katsuo Inaya
Contact: https://www.ntt-precisionmedicine.co.jp/contact/?service=5
BC Platforms
Communications Manager
Tatiana Sachs
Email: tatiana.sachs [at]bcplatforms.com
References and Notes
*1 About "JPP"
JPP Service Website https://www.ntt-precisionmedicine.co.jp/service/jpp/
*2 Federated Analytics Technology
This is a foundation enabling secure analysis of real-world data (RWD) across multiple healthcare institutions using internationally standardized "Federated Analytics" technology, without moving patient data externally.
Rather than centrally collecting or transferring data externally, it employs a mechanism where each healthcare institution retains its data. Only the analysis logic based on common specifications is distributed, and only the necessary aggregated results are returned.
This achieves:
- high security preventing the removal of personal or sensitive data,
- highly reproducible analysis through a unified data model (e.g., OMOP CDM) across facilities,
- ease of collaboration with domestic and international medical and research institutions,
- and accelerated cross-disease cohort exploration and epidemiological research by pharmaceutical companies are achieved.
Furthermore, when combined with the Trusted Research Environment, it ensures a "secure and verifiable access process" for non-anonymized in-house data, supporting the creation of an environment enabling researchers to conduct more advanced analyses.
BC Platforms’ products are used by leading medical and research institutions, primarily in Europe, North America, and the Asia-Pacific region, and are increasingly being adopted as the standard technology for international real-world data analysis.
*3 TRE : Trusted Research Environment
A TRE is a secure, controlled computing environment where sensitive health data can be accessed and analyzed without exposing or transferring the raw data. It is designed to protect patient privacy while still enabling meaningful research.
Related Press Releases
1. Partnership Agreement
October 3, 2023
Collaboration for Creating New Value in the Medical Field through Data-Driven Technology
- Establishment of the "Global Medical Data Highway" - a secure sharing platform for medical data - for the advancement of next-generation medical care –
https://group.ntt/en/newsrelease/2023/10/03/231003a.html
https://www.ntt-precisionmedicine.co.jp/news/single/?id=20231003
https://prime-r.inc/newsrelease/658/
https://www.bcplatforms.com/news/bc-platforms-partners-with-ntt-to-accelerate-data-driven-medicine-in-japan
2. The Launch of JPP
April 15, 2024
Accelerating data-driven medical research through a platform that can securely distribute and utilize medical data
NTT Life Science Corporation launches Japan Precision Medicine PlatformTM
https://group.ntt/en/newsrelease/2024/04/15/240415a.html
https://www.ntt-precisionmedicine.co.jp/news-jpp/single/?id=53r1loyjm
https://prime-r.inc/newsrelease/736/
https://www.bcplatforms.com/news/bc-platforms-and-ntt-group-announce-official-opening-ceremony-for-exclusive-collaboration-and-launch-of-japanese-precision-medicine-platform
3. The Launch of the JPP Center
March 31, 2025
JPP Center, Revolutionizing Medical Data Utilization, Begins Full-Scale Operations ~ Advanced Data Exploration and Analysis Platform Supporting Next-Generation Medical Research ~
https://www.ntt-precisionmedicine.co.jp/news-jpp/single/?id=20250331
Reference
About BC Platforms
BC Platforms accelerates medical innovation through advanced technology, predictive analytics, and comprehensive healthcare data. The combination of our harmonized multi-modal, research-ready datasets, unique federated architecture, and purpose-built AI-powered platforms enables rapid insights and informed decision-making for precision medicine and the full drug lifecycle. Leading life sciences companies and healthcare organizations rely on BC Platforms technology for secure access to real-world clinical and genomic data, sourced from our global partner network representing over 175 million patients across more than 35 countries.
Company Name: BC Platforms
Location: Zurich
Established: 1997
Representative: CEO Mukhtar Ahmed
https://www.linkedin.com/company/bc-platforms/
Implementation Track Record
・Enables cloud-based analysis of clinical data for 175 million people across more than 35 countries worldwide
・Implemented at RIKEN(Institute of Physical and Chemical Research) in 2020 and JIHS: Japan Institute for Health Security (formerly NCGM: National Center for Global Health and Medicine)) in 2023